Taiwan Stock Market Ends Higher as Semiconductor and Energy Shares Lead Gains 
US and Japan Fast-Track $550 Billion Strategic Investment Initiative 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Asian Markets Rise as AI Rally Caps 2025, Gold and Silver Hit Record Highs 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Japan Plans $189 Billion Bond Issuance as Record Budget Signals Expansionary Fiscal Policy 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Oil Prices Edge Higher as Strong U.S. Growth and Supply Risks Support Market 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Japan to Audit Brazil’s Beef System, Paving Way for Market Access 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
SK bioscience Co. will invest $1.79 billion by 2027 to expand its contract manufacturing capabilities to strengthen its readiness for the next pandemic, expand its overseas operations, and seize new business opportunities.
The proposed investment is twice the amount the company had spent in the past five years.
Of the total investment, t half would be spent on research and development (R&D) and the construction of a new R&D campus in Songdo, Incheon, which is expected to be completed in 2025.
SK bioscience has manufactured the COVID-19 vaccines of AstraZeneca and Novavax in South Korea under a partnership deal.
The company is seeking to ink deals with major pharmaceutical companies within the year, according to SK bioscience CEO Ahn Jae-yong.
"A deal could come as early as within the first half of this year," he said.
Also, the company has been looking for a possible merger deal in the United States in the field of cell and gene therapy.
The company swung to a deficit for the January-March period as waning demand led to a drop in the production of licensed COVID-19 vaccines. Its loss amounted to 29.2 billion won, compared with a profit of 23.8 billion won a year ago.
Ahn expected the company to make a turnaround in three years after investing aggressively in building up the foundations for future growth.
